MoonLake's Sonelokimab Trial Results for Hidradenitis Suppurativa: What Happened?
MoonLake announced Phase 3 results for sonelokimab (VELA trials) in HS. While one trial succeeded using the primary analysis, the other faced challenges due to a high placebo response, leading to a stock downgrade.